Interleukin-21 is a critical regulator of CD4 and CD8 T cell survival during priming under Interleukin-2 deprivation conditions.
Interleukin-21 is a critical regulator of CD4 and CD8 T cell survival during priming under Interleukin-2 deprivation conditions.
复制标题
DOI:
10.1371/journal.pone.0085882
复制
发表时间:
2014
期刊:
影响因子:
3.7
通讯作者:
Stepkowski SM
中科院分区:
文献类型:
--
作者:
Khattar M;Miyahara Y;Schroder PM;Xie A;Chen W;Stepkowski SM
Optimal T cell activation and expansion require binding of the common gamma-chain (γc) cytokine Interleukin-2 (IL-2) to its cognate receptor that in turn engages a γc/Janus tyrosine kinase (Jak)3 signaling pathway. Because of its restricted expression by antigen-activated T cells and its obligatory role in promoting their survival and proliferation, IL-2 has been considered as a selective therapeutic target for preventing T cell mediated diseases. However, in order to further explore IL-2 targeted therapy, it is critical to precisely understand its role during early events of T cell activation. In this study, we delineate the role of IL-2 and other γc cytokines in promoting the survival of CD4 and CD8 T cells during early phases of priming. Under IL-2 inhibitory conditions (by neutralizing anti-IL-2 mAbs), the survival of activated CD8+ T cells was reduced, whereas CD4+ T cells remained much more resistant. These results correlated with reduced Bcl-2 expression, and mitochondrial membrane potential in CD8+ T cells in comparison to CD4+ T cells. However, using transwell co-culture assays we have found that CD4+ T cells could rescue the survival of CD8+ T cells even under IL-2 deprived conditions via secretion of soluble factors. A cytokine screen performed on CD8+ T cells cultured alone revealed that IL-21, another γc cytokine, was capable of rescuing their survival under IL-2 deprivation. Indeed, blocking the IL-21 signaling pathway along with IL-2 neutralization resulted in significantly reduced survival of both CD4+ and CD8+ T cells. Taken together, we have shown that under IL-2 deprivation conditions, IL-21 may act as the major survival factor promoting T cell immune responses. Thus, investigation of IL-2 targeted therapies may need to be revisited to consider blockade of the IL-21 signaling pathways as an adjunct to provide more effective control of T cell immune responses.
登录
查看更多内容
DOI:
10.4049/jimmunol.1200751
发表时间:
2013-04-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Guo Z;Khattar M;Schroder PM;Miyahara Y;Wang G;He X;Chen W;Stepkowski SM
通讯作者:
Stepkowski SM
影响因子:
82.9
作者:
通讯作者:
--
DOI:
10.1084/jem.20111174
发表时间:
2012-02-13
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Johnston RJ;Choi YS;Diamond JA;Yang JA;Crotty S
通讯作者:
Crotty S
影响因子:
7.7
作者:
McGuire HM;Walters S;Vogelzang A;Lee CM;Webster KE;Sprent J;Christ D;Grey S;King C
通讯作者:
King C
影响因子:
6.2
作者:
Borie, DC;Changelian, PS;Morris, RE
通讯作者:
Morris, RE